{"id":152392,"date":"2020-08-18T08:55:29","date_gmt":"2020-08-18T12:55:29","guid":{"rendered":"https:\/\/www.ocorreionews.com.br\/acervo-correio\/?p=152392"},"modified":"2020-08-18T08:55:29","modified_gmt":"2020-08-18T12:55:29","slug":"anvisa-autoriza-testes-de-mais-uma-vacina-contra-covid-19-no-brasil","status":"publish","type":"post","link":"https:\/\/www.ocorreionews.com.br\/acervo-correio\/?p=152392","title":{"rendered":"Anvisa autoriza testes de mais uma vacina contra Covid-19 no Brasil"},"content":{"rendered":"<div class=\"mc-column content-text active-extra-styles \" data-block-type=\"unstyled\" data-block-weight=\"51\" data-block-id=\"2\">\n<p class=\"content-text__container \" data-track-category=\"Link no Texto\" data-track-links=\"\">A Anvisa (Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria) autorizou, nesta ter\u00e7a-feira (18), testes de fase 3 de mais uma vacina contra a Covid-19 no Brasil: a <strong>Ad26.COV2.S, <\/strong>desenvolvida pela Janssen Pharmaceuticals, do grupo Johnson &amp; Johnson. Esta \u00e9 a quarta vacina a obter autoriza\u00e7\u00e3o de testes no pa\u00eds (<em>veja detalhes mais abaixo<\/em>).<\/p>\n<p data-track-category=\"Link no Texto\" data-track-links=\"\">\n<\/div>\n<div class=\"wall protected-content\">\n<div class=\"mc-column content-text active-extra-styles \" data-block-type=\"unstyled\" data-block-weight=\"35\" data-block-id=\"3\">\n<p class=\"content-text__container \" data-track-category=\"Link no Texto\" data-track-links=\"\">Est\u00e1 prevista a participa\u00e7\u00e3o de 7 mil volunt\u00e1rios, com idade m\u00ednima de 18 anos, em 7 estados: Bahia, Minas Gerais, Paran\u00e1, Rio de Janeiro, Rio Grande do Norte, Rio Grande do Sul e S\u00e3o Paulo.<\/p>\n<p data-track-category=\"Link no Texto\" data-track-links=\"\">\n<\/div>\n<div class=\"mc-column content-text active-extra-styles \" data-block-type=\"unstyled\" data-block-weight=\"30\" data-block-id=\"4\">\n<p class=\"content-text__container \" data-track-category=\"Link no Texto\" data-track-links=\"\">Na fase 3, \u00e9 testada a seguran\u00e7a e a efic\u00e1cia de uma imuniza\u00e7\u00e3o, normalmente com participa\u00e7\u00e3o de milhares de volunt\u00e1rios. Existem outras tr\u00eas vacinas sendo testadas nesta etapa no Brasil:<\/p>\n<\/div>\n<div data-track-category=\"multicontent\" data-track-action=\"ultimo chunk conteudo\" data-track-noninteraction=\"false\" data-track-scroll=\"view\">\n<div class=\"mc-column content-text active-extra-styles\" data-block-type=\"raw\" data-block-weight=\"12\" data-block-id=\"5\">\n<p class=\"content-text__container\">\n<ol class=\"content-ordered-list theme-ordered-list-color-primary\">\n<li>a de Oxford (inglesa);<\/li>\n<li>a da Sinovac (chinesa);<\/li>\n<li>a da BioNTech\/Pfizer (alem\u00e3\/americana).<\/li>\n<\/ol>\n<\/div>\n<\/div>\n<\/div>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>G1<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A Anvisa (Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria) autorizou, nesta ter\u00e7a-feira (18), testes de fase 3 de mais uma vacina contra a Covid-19 no Brasil: a Ad26.COV2.S, desenvolvida pela Janssen Pharmaceuticals, do grupo Johnson &amp; Johnson. Esta \u00e9 a quarta vacina a obter autoriza\u00e7\u00e3o de testes no pa\u00eds (veja detalhes mais abaixo). Est\u00e1 prevista a participa\u00e7\u00e3o [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":145968,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[39],"tags":[],"class_list":["post-152392","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-saude"],"_links":{"self":[{"href":"https:\/\/www.ocorreionews.com.br\/acervo-correio\/index.php?rest_route=\/wp\/v2\/posts\/152392","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ocorreionews.com.br\/acervo-correio\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ocorreionews.com.br\/acervo-correio\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ocorreionews.com.br\/acervo-correio\/index.php?rest_route=\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ocorreionews.com.br\/acervo-correio\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=152392"}],"version-history":[{"count":1,"href":"https:\/\/www.ocorreionews.com.br\/acervo-correio\/index.php?rest_route=\/wp\/v2\/posts\/152392\/revisions"}],"predecessor-version":[{"id":152394,"href":"https:\/\/www.ocorreionews.com.br\/acervo-correio\/index.php?rest_route=\/wp\/v2\/posts\/152392\/revisions\/152394"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ocorreionews.com.br\/acervo-correio\/index.php?rest_route=\/wp\/v2\/media\/145968"}],"wp:attachment":[{"href":"https:\/\/www.ocorreionews.com.br\/acervo-correio\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=152392"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ocorreionews.com.br\/acervo-correio\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=152392"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ocorreionews.com.br\/acervo-correio\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=152392"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}